Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $19.2 million.

  • Journey Medical's Operating Expenses rose 934.2% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year decrease of 1437.2%. This contributed to the annual value of $69.8 million for FY2024, which is 1408.3% down from last year.
  • Journey Medical's Operating Expenses amounted to $19.2 million in Q3 2025, which was up 934.2% from $17.9 million recorded in Q2 2025.
  • Journey Medical's 5-year Operating Expenses high stood at $32.3 million for Q3 2021, and its period low was $10.1 million during Q1 2021.
  • For the 5-year period, Journey Medical's Operating Expenses averaged around $21.3 million, with its median value being $21.8 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 25030.41% in 2021, then plummeted by 3441.62% in 2024.
  • Journey Medical's Operating Expenses (Quarter) stood at $26.6 million in 2021, then fell by 2.31% to $26.0 million in 2022, then tumbled by 33.13% to $17.4 million in 2023, then crashed by 34.42% to $11.4 million in 2024, then soared by 68.28% to $19.2 million in 2025.
  • Its Operating Expenses was $19.2 million in Q3 2025, compared to $17.9 million in Q2 2025 and $16.5 million in Q1 2025.